tetano
Editor, Senior Moderator
J Public Health Afr
. 2024 Nov 7;15(1):649.
doi: 10.4102/jphia.v15i1.649. eCollection 2024. High immunity and low mortality after Omicron and mass event in Cameroon despite low vaccination
Yap Boum[SUP] 1 2 3 [/SUP], Lucrece Matchim[SUP] 2 [/SUP], Dominique K Guimsop[SUP] 4 5 [/SUP], Bongkiyung D Buri[SUP] 2 [/SUP], Lisa M Bebell[SUP] 6 [/SUP], Yuya S F Jaudel[SUP] 7 [/SUP], Fai K G Njuwa[SUP] 2 [/SUP], Daniel B Danirla[SUP] 2 [/SUP], Eric Youm[SUP] 7 [/SUP], Rodrigue Ntone[SUP] 2 [/SUP], Claudric Roosevelt Tchame[SUP] 4 [/SUP], Dora Tchiasso[SUP] 2 [/SUP], Rachelle Essaka[SUP] 8 [/SUP], Justin B Eyong[SUP] 2 [/SUP], Audrey Ngosso[SUP] 2 [/SUP], Herwin Nanda[SUP] 2 [/SUP], Nsaibirni R Fondze[SUP] 7 [/SUP], Mark Ndifon Ndifon[SUP] 7 [/SUP], Lucrèce Eteki[SUP] 2 [/SUP], Yonta F C Ghislain[SUP] 2 [/SUP], Bruno Yannick Eyenga Messi[SUP] 2 [/SUP], Hamadou Moustapha[SUP] 2 [/SUP], Moustafa Hamdja[SUP] 2 [/SUP], René Ghislain Essomba[SUP] 9 [/SUP], Nadia Mandeng[SUP] 1 [/SUP], Tamakloe A K Modeste[SUP] 10 [/SUP], Anne-Cécile Zoung-Kani Bisseck[SUP] 11 [/SUP], Sara Irène Eyangoh[SUP] 12 [/SUP], Richard Njouom[SUP] 12 [/SUP], Marie Claire Okomo[SUP] 9 [/SUP], Linda Esso[SUP] 1 13 [/SUP], Epee Emilienne[SUP] 1 4 [/SUP], Georges-Alain Etoundi Mballa[SUP] 1 4 [/SUP]
Affiliations
Background: Little is known about the evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunity in African communities.
Aim: We evaluated changes in anti-SARS-CoV-2 antibodies, mortality and vaccination status in Cameroon between August 2021 and September 2022 to begin describing the evolution of the pandemic in Africa.
Setting: The study was conducted across Cameroon's 10 regional capitals, between 2021 and 2022 as the country hosted a mass gathering.
Methods: We conducted a cross-sectional population-based survey in 2022, including SARS-CoV-2 seroprevalence testing and retrospective mortality estimation using two-stage cluster sampling. We estimated and compared seroprevalence and crude mortality rates (CMR) to a survey conducted in 2021 using the same methodology.
Results: We performed serologic testing on 8400 individuals and collected mortality data from 22 314 individuals. Approximately 5% in each survey reported SARS-CoV-2-vaccination. Rapid diagnostic test-based seroprevalence increased from 11.2% (95% confidence interval [CI]: 10-12.5) to 59.8% (95% CI: 58.3-61.2) between 2021 and 2022, despite no increase in the proportion vaccinated. The CMR decreased from 0.17 to 0.06 deaths per 10 000 persons per day between 2021 and 2022. In 2022, no deaths were reportedly attributable to COVID-19 as compared to 17 deaths in 2021.
Conclusion: Over a 12-month period encompassing two waves of omicron variant SARS-CoV-2 and a mass gathering, SARS-CoV-2 seropositivity in Cameroon approached 60%, and deaths declined despite low vaccination coverage.
Contribution: This study challenges the assumption that high immunisation coverage is the sole determinant of epidemic control in the African context and encourages policymakers to increasingly rely on local research when designing response strategies for more effective outbreak management.
Keywords: Africa; SARS-CoV-2; immunity; mortality; seroprevalence.
. 2024 Nov 7;15(1):649.
doi: 10.4102/jphia.v15i1.649. eCollection 2024. High immunity and low mortality after Omicron and mass event in Cameroon despite low vaccination
Yap Boum[SUP] 1 2 3 [/SUP], Lucrece Matchim[SUP] 2 [/SUP], Dominique K Guimsop[SUP] 4 5 [/SUP], Bongkiyung D Buri[SUP] 2 [/SUP], Lisa M Bebell[SUP] 6 [/SUP], Yuya S F Jaudel[SUP] 7 [/SUP], Fai K G Njuwa[SUP] 2 [/SUP], Daniel B Danirla[SUP] 2 [/SUP], Eric Youm[SUP] 7 [/SUP], Rodrigue Ntone[SUP] 2 [/SUP], Claudric Roosevelt Tchame[SUP] 4 [/SUP], Dora Tchiasso[SUP] 2 [/SUP], Rachelle Essaka[SUP] 8 [/SUP], Justin B Eyong[SUP] 2 [/SUP], Audrey Ngosso[SUP] 2 [/SUP], Herwin Nanda[SUP] 2 [/SUP], Nsaibirni R Fondze[SUP] 7 [/SUP], Mark Ndifon Ndifon[SUP] 7 [/SUP], Lucrèce Eteki[SUP] 2 [/SUP], Yonta F C Ghislain[SUP] 2 [/SUP], Bruno Yannick Eyenga Messi[SUP] 2 [/SUP], Hamadou Moustapha[SUP] 2 [/SUP], Moustafa Hamdja[SUP] 2 [/SUP], René Ghislain Essomba[SUP] 9 [/SUP], Nadia Mandeng[SUP] 1 [/SUP], Tamakloe A K Modeste[SUP] 10 [/SUP], Anne-Cécile Zoung-Kani Bisseck[SUP] 11 [/SUP], Sara Irène Eyangoh[SUP] 12 [/SUP], Richard Njouom[SUP] 12 [/SUP], Marie Claire Okomo[SUP] 9 [/SUP], Linda Esso[SUP] 1 13 [/SUP], Epee Emilienne[SUP] 1 4 [/SUP], Georges-Alain Etoundi Mballa[SUP] 1 4 [/SUP]
Affiliations
- PMID: 39649435
- PMCID: PMC11622603
- DOI: 10.4102/jphia.v15i1.649
Background: Little is known about the evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunity in African communities.
Aim: We evaluated changes in anti-SARS-CoV-2 antibodies, mortality and vaccination status in Cameroon between August 2021 and September 2022 to begin describing the evolution of the pandemic in Africa.
Setting: The study was conducted across Cameroon's 10 regional capitals, between 2021 and 2022 as the country hosted a mass gathering.
Methods: We conducted a cross-sectional population-based survey in 2022, including SARS-CoV-2 seroprevalence testing and retrospective mortality estimation using two-stage cluster sampling. We estimated and compared seroprevalence and crude mortality rates (CMR) to a survey conducted in 2021 using the same methodology.
Results: We performed serologic testing on 8400 individuals and collected mortality data from 22 314 individuals. Approximately 5% in each survey reported SARS-CoV-2-vaccination. Rapid diagnostic test-based seroprevalence increased from 11.2% (95% confidence interval [CI]: 10-12.5) to 59.8% (95% CI: 58.3-61.2) between 2021 and 2022, despite no increase in the proportion vaccinated. The CMR decreased from 0.17 to 0.06 deaths per 10 000 persons per day between 2021 and 2022. In 2022, no deaths were reportedly attributable to COVID-19 as compared to 17 deaths in 2021.
Conclusion: Over a 12-month period encompassing two waves of omicron variant SARS-CoV-2 and a mass gathering, SARS-CoV-2 seropositivity in Cameroon approached 60%, and deaths declined despite low vaccination coverage.
Contribution: This study challenges the assumption that high immunisation coverage is the sole determinant of epidemic control in the African context and encourages policymakers to increasingly rely on local research when designing response strategies for more effective outbreak management.
Keywords: Africa; SARS-CoV-2; immunity; mortality; seroprevalence.